Second Anti-HER2 TKI Approved for NSCLC

Bayer’s sevabertinib picks up a second-line indication for HER2-mutated disease, joining Boehringer’s zongertinib on the US market.
Medscape Medical News

Source link : https://www.medscape.com/viewarticle/second-anti-her2-tki-approved-nsclc-2025a1000wan?src=rss

Author :

Publish date : 2025-11-19 20:59:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

Second Anti-HER2 TKI Approved for NSCLC

Better Survival in Kidney Cancer After Stopping Therapy for Immune-Related AEs

New FDA-Approved Option for HER2-Mutated Lung Cancer

Related Posts

IL-6 Vaccine Shows Early Benefit in Knee Osteoarthritis

Helping Patients Transition From Pediatrics to Your Practice

Lower Risk Groups Can Cut Back on Cervical Cancer Screening

Should I buy a flu vaccine this year?

AI Improves Endoscopy Scoring in Ulcerative Colitis

Women With Chronic Severe CAD Fare Better With CABG vs PCI

IL-6 Vaccine Shows Early Benefit in Knee Osteoarthritis

Helping Patients Transition From Pediatrics to Your Practice

Lower Risk Groups Can Cut Back on Cervical Cancer Screening

Should I buy a flu vaccine this year?

AI Improves Endoscopy Scoring in Ulcerative Colitis

Women With Chronic Severe CAD Fare Better With CABG vs PCI

Masks to be worn as flu hits Berkshire and Surrey hospitals

eConsults Improve Rheumatology Care Access and Delivery

Categories

Archives